West Pharmaceutical Defies Doubters: EPS Jumps, Outlook Raised Despite Tariff Drag

West Pharmaceutical topped Q1 estimates and raised 2025 guidance, citing stronger device demand and improved inventory trends across key markets. Latest Ratings for WST Date Firm Action From To Jul 2021 Keybanc Maintains Overweight Nov 2020 Keybanc Initiates Coverage On Overweight Oct 2020 Stephens & Co. Initiates Coverage On Equal-Weight View More Analyst Ratings for…

Read More

Tariff Relief for NextEra? Goldman Sachs Says Limited Exposure A Key Positive

Goldman Sachs analyst reiterated Buy rating for NextEra Energy with $91 price target, reporting better-than-expected EPS but falling short on sales. Latest Ratings for NEE Date Firm Action From To Mar 2022 Keybanc Upgrades Sector Weight Overweight Feb 2022 Morgan Stanley Maintains Equal-Weight Jan 2022 Wells Fargo Maintains Overweight View More Analyst Ratings for NEE…

Read More